BRCA1 and breast carcinoma: In breast cancer, OlympiAD demonstrated olaparib’s benefit in prolonging PFS for HER2-negative, BRCA1/2-mutated metastatic patients [15], and EMBRACA confirmed similar efficacy for talazoparib [16].